Middle East and Africa Generic Injectables Market Report and Forecast 2024-2032

Middle East and Africa Generic Injectables Market Analysis

Generic injectables are high-quality bioequivalent versions of expensive innovator injectables, typically marketed at a lower price. These pharmaceutical products are injected either by a healthcare worker or the patients themselves and are used in certain clinical settings such as cancer care, trauma, and surgery, due to their rapid onset of action and higher bioavailability. There is a growing focus on the development of novel formulations of these faster-acting generics in oncology and specialty therapeutic areas, which is influencing the global generic injectables market landscape. Further, several generic manufacturers are increasingly investing in expanding their generic injectable portfolio to meet the growing healthcare demand, which is expected to fuel the Middle East and Africa generic injectables market growth.

The Middle Eastern and African countries are heavily investing in the healthcare and pharmaceutical sectors which has substantially affected the market demand. Recent data reveals that the size of the pharmaceutical market in Saudi Arabia has witnessed a massive increase, with most of the national pharmaceutical industries focused on the production of generics. Additionally, local manufacturing of generic injectables was estimated to be 30% out of all dosage forms in the region. This growth of local generic pharmaceutical manufacturing capabilities and capacities, supported by both public and private investments, is projected to boost the Middle East and Africa generic injectables market share.

One of the major market trends is the rise in strategic partnerships between public and private bodies to address global health challenges. For instance, in March 2023 , multinational pharmaceutical company GlaxoSmithKline (GSK plc) issued voluntary licenses to three companies (Aurobindo Pharma, Cipla, and Viatris) to manufacture generic versions of its HIV preventive medicine (injectable drug cabotegravir). This deal is likely to expedite market penetration of this injectable in lower-income countries. Further, Indian drugmaker Cipla reported plans to manufacture the generic injection in South Africa. Moreover, GSK also announced a public-private partnership with the Medicines Patent Pool (a United Nations-backed healthcare organization) in July 2022, to accelerate access to new HIV therapies in poor countries, with the introduction of its generic injectables expected by 2026. Such licensing agreements indicate an emphasis on increasing access to cost-effective medications which is anticipated to elevate the market value in the forecast period.

Middle East and Africa Generic Injectables Market Report Snapshots

Middle East and Africa Generic Injectables Market Size

Middle East and Africa Generic Injectables Market Analysis

Middle East and Africa Generic Injectables Companies